We hope everyone will join us at the PGRN 2026 Scientific Meeting in Collaboration with ClinPGx in Chicago from September 25 (pre-conference day)-27. The ClinPGx User Meeting will be held on Saturday, September 26 at 8 am and is open to all conference attendees, from first-time ClinPGx visitors to experienced users, researchers, educators, and professionals implementing pharmacogenomics in clinical practice. We will have a brief introduction and update on future directions for ClinPGx and CPIC

PharmVar released changes and additions to the CYP2C19 allele definitions which includes an update of the CYP2C19*2 core allele definition. Prior to the latest release, the CYP2C19*2 allele was defined by three core variants, c.332-23A>G (splice defect), c.681G>A (splice defect) and c.991A>G (p.I331V, which is present in most CYP2C19 alleles including CYP2C19*1). The publication "CYP2C19 c.681G>A Is not in Complete Linkage Disequilibrium With c.332-23A>G: Implications for Pharmacogenetic Testi

Register now for the upcoming PGRN/ClinPGx meeting - early bird registration ends July 27! This year's meeting is being held September 26-27 at Northwestern University in Chicago. The conference kicks off with a networking breakfast, including a ClinPGx User meeting (additional details to come), then a keynote from Dr. Deepak Voora, followed by two days of exciting scientific programming. Additionally, on September 25, there is a pre-conference day with three sessions offered: Applying Implemen

We would like to improve the drug categories that are used on the PharmDOG and the GSI results pages to group annotated drugs and are asking the user community to help us out by responding to our survey. Currently, drugs are grouped using the World Health Organization's Anatomical Therapeutic Chemical (ATC) Classification. ClinPGx uses ATC groupings throughout the website, but we've received feedback that this classification is not intuitive to clinicians. Unfortunately, most drug classificatio

PharmCAT has a new release. This is an update to the recently announced PharmCAT 3.3.0 release that includes some minor bugfixes and a PharmVar update. Changelog Features * data: update from PharmVar for newly released CYP2C9 alleles (8ff5870) Bug Fixes * recommend bcftools 1.24 (adfef81) * reporter: fix bug when >1 phenotype applies to a single gene (c0e5a1f)

We are excited to announce our latest release! This update is highly recommended. It fixes an issue with pharmcat_pipeline where it uses the original input VCF instead of the preprocessed VCF if it is given a directory instead of a file. Data highlights * PharmVar: new alleles were released for CYP2C9, CYP2D6, CYP3A4, CYP3A5, NUDT15 * ClinPGx: * updates released/published for the CPIC Guideline for RYR1, CACNA1S and Volatile anesthetic agents and Succinylcholine and the CPIC Guideline f

Although the updated CPIC guideline for DPYD and fluoropyrimidines is still in development, the authors have concluded, based on current evidence, that c.1129-5923C>G, the minor allele at rs75017182 and causal allele associated with the “HapB3” haplotype, will be assigned an allele value of 0.75. For a heterozygous carrier, this corresponds to an activity score of 1.75. For these patients, the recommendation is to initiate treatment at 75% of the intended dose in cycle 1. The intended dose refer

As part of our transition from PharmGKB to ClinPGx, we're retiring the old API hostname, api.pharmgkb.org, in favor of api.clinpgx.org. What's changing If your code, scripts, or integrations call the API at api.pharmgkb.org, you'll need to update them to use api.clinpgx.org instead. The good news: the switch is a simple find-and-replace. All endpoints, paths, and response formats are unchanged — only the hostname is different. - https://api.pharmgkb.org/v1/... + https://api.clinpgx.org/v1/..

A correction to Table 1 of the "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2025 Update" was published in Clinical Pharmacology and Therapeutics. An individual carrying one no function allele plus one decreased function allele is an Intermediate Metabolizer (IM), not a Possible Intermediate Metabolizer as shown in the original table. The therapeutic recommendations for TPMT IMs and Possible IMs are the same. The

We want to inform everyone of some things that are changing (and some things that are not) in the CPIC database and API. CPIC and ClinPGx CPIC is now part of ClinPGx. The standalone CPIC site will retire soon, but all its content will move to ClinPGx. Visiting cpicpgx.org will redirect you to the corresponding ClinPGx page. We’re not planning any changes to the CPIC database or API. The database stays on GitHub at the releases page, and the API remains at https://api.cpicpgx.org. If we need

The Clinical Pharmacogenetics Implementation Consortium is moving to the ClinPGx website. All CPIC information will still be available in a similar format. All current and published CPIC URLs should re-direct to equivalent pages on the ClinPGx website, so existing bookmarks and links should not break. We plan for CPIC URLs to re-direct starting March 9, 2026. The website move does not affect the CPIC DB or API. As always, if you experience any issues, please let us know at feedback@clinpgx.org.

CPIC is currently evaluating evidence on antipsychotics and CYP2D6, CYP3A4 and CYP2C19 for the development of guidelines. To support this ClinPGx curators have expanded our set of antipsychotics pathways; updating and developing some of our in progress pathways and curating some new ones.

The Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2025 Update has been published in Clinical Pharmacology and Therapeutics (PMID:41618934). The guideline contains multiple updates to the previous recommendations for adjusting the starting doses of azathioprine, mercaptopurine and thioguanine according to the combination of TPMT and NUDT15 phenotypes derived from genotypes and the specific indication (i.e. malignant

Highlights of the latest releases (v3.1.0- v3.1.1) are: * CPIC function and phenotype assignments are used to provide genotype-level guidance from all sources including DPWG and FDA. For a detailed blog see, Genotype-Phenotype Mapping for Guideline and Drug Label Curation. * Allele definitions are up to date to PharmVar’s  Version 6.2.17.2, which adds new alleles for NAT2, CYP2C19, CYP2C9, SLCO1B1. * Recommendation updates (see full list of gene and drugs included in PharmCAT) * Addition

ClinPGx now uses CPIC/ClinPGx allele function and phenotype mappings and terms for guideline and drug label curation, including the interactive genotype picker tools on DPWG guideline annotation pages. If a DPWG guideline gene is not a CPIC gene, then we will continue to use DPWG mappings based on documents previously downloaded from the KNMP website. The DPWG terms and mapping largely agree with CPIC/ClinPGx across genes, but exceptions are noted on the DPWG mappings page. We will also continue

The FDA-approved label for Xeloda (capecitabine) was updated a week ago to include a boxed warning regarding adverse reactions in patients with complete DPD deficiency and to "Test patients for genetic variants of DPYD prior to initiating XELODA unless immediate treatment is necessary." This language is new. The previous version of the label recommended against using the drug "in patients known to have certain homozygous or compound heterozygous DPYD variants that result in complete DPD deficie

The CPIC Guideline for NAT2 Genotype and Hydralazine Therapy has been published in the journal Clinical Pharmacology and Therapeutics. This new guideline summarizes and evaluates literature evidence regarding the impact of genetic variants on NAT2's metabolism of hydralazine, a vasodilator typically used in the treatment of resistant hypertension and heart failure, into inactive metabolites. This is the first CPIC guideline for NAT2 (N-acetyltransferase 2). From the guideline: "NAT2 poor metabol

We are excited to announce the publication of Toward an integrated resource for pharmacogenomics (PGx): Survey findings from the genomic medicine communities (PMID: 40662343) by the ClinGen Pharmacogenomics Interpretation Committee (PGxIC) in Genetics in Medicine. This publication covers the results of the PGxIC’s two needs assessment surveys targeting both the pharmacogenomics and genomic medicine communities, and can be read at this link free of charge until October 2, 2025. We thank all of

We’re excited to announce that our latest paper, titled “Towards an Integrated Resource for Pharmacogenomics (PGx): Survey Findings from the Genomic Medicine Communities,” is now in press in Genetics in Medicine! This work, conducted by the ClinGen Pharmacogenomics Interpretation Committee (PGxIC, formerly the PGx Working Group), presents findings from two community surveys that gathered perspectives from over 500 participants across the PGx and genomic medicine communities. The goal of the sur

Nearly two years ago, we introduced the vision for ClinPGx to integrate the PharmGKB, CPIC and PharmCAT projects into a unified resource. In June 2024, we launched the ClinPGx blog and held the first ClinPGx Meeting. We are excited to announce that over the coming weeks, PharmGKB will officially become ClinPGx. Once the new ClinPGx website debuts, there will be a brief period where both websites will co-exist.  At the end of this period, PharmGKB URLs will automatically redirect users to the eq

PharmGKB is conducting a survey designed to gather user feedback to enhance our content, features and tools. Your insights are essential as PharmGKB transitions to ClinPGx this summer and we prepare our next grant application to support our ongoing project. We would be incredibly grateful for your thoughts on the relevance and value of the PharmGKB website. The survey is designed to be quick and easy, consisting of two parts: (1) a brief section that takes approximately 1 minute to complete, an

We are excited to announce that we have partnered with Dr. Emily Cicali on behalf of The University of Florida Health Precision Medicine Program to incorporate the information presented in the PROPTM pharmacogenetics calculator into the GSI. Users can select from a list of concomitant medications that are either strong or moderate CYP2D6 inhibitors to account for CYP2D6 phenoconversion. Additionally, the following updates have been made: * Users can now enter gene phenotypes as input as well